Wooridul Huebrain Limited (118000.KS)
KRW 298.0
(-1.32%)
KRW 298.0
(-1.32%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 55.75 Billion KRW | 191.91% |
| 2022 | 19.09 Billion KRW | 2.61% |
| 2021 | 18.61 Billion KRW | -30.8% |
| 2020 | 26.89 Billion KRW | -52.1% |
| 2019 | 56.15 Billion KRW | 62.9% |
| 2018 | 34.47 Billion KRW | -6.53% |
| 2017 | 36.88 Billion KRW | 228.33% |
| 2016 | 11.23 Billion KRW | -1.9% |
| 2015 | 11.45 Billion KRW | -2.65% |
| 2014 | 11.76 Billion KRW | -5.64% |
| 2013 | 12.46 Billion KRW | -44.14% |
| 2012 | 22.31 Billion KRW | -35.11% |
| 2011 | 34.38 Billion KRW | 16.94% |
| 2010 | 29.4 Billion KRW | 758.01% |
| 2009 | 3.42 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 4.88 Billion KRW | -88.63% |
| 2024 Q2 | 4.86 Billion KRW | -0.39% |
| 2023 FY | 55.75 Billion KRW | 191.91% |
| 2023 Q2 | 10.43 Billion KRW | 1.15% |
| 2023 Q1 | 10.31 Billion KRW | 154.33% |
| 2023 Q4 | 42.96 Billion KRW | 910.14% |
| 2023 Q3 | 4.25 Billion KRW | -59.24% |
| 2022 FY | 19.09 Billion KRW | 2.61% |
| 2022 Q2 | 4.96 Billion KRW | -6.09% |
| 2022 Q1 | 5.28 Billion KRW | 118.34% |
| 2022 Q3 | 4.79 Billion KRW | -3.44% |
| 2022 Q4 | 4.05 Billion KRW | -15.39% |
| 2021 Q3 | 7.4 Billion KRW | 3.34% |
| 2021 Q1 | 1.63 Billion KRW | -81.38% |
| 2021 FY | 18.61 Billion KRW | -30.8% |
| 2021 Q2 | 7.16 Billion KRW | 339.06% |
| 2021 Q4 | 2.42 Billion KRW | -67.29% |
| 2020 Q4 | 8.76 Billion KRW | 47.23% |
| 2020 Q2 | 8.28 Billion KRW | 112.34% |
| 2020 Q1 | 3.9 Billion KRW | -75.73% |
| 2020 FY | 26.89 Billion KRW | -52.1% |
| 2020 Q3 | 5.95 Billion KRW | -28.18% |
| 2019 Q1 | 6.37 Billion KRW | -35.3% |
| 2019 FY | 56.15 Billion KRW | 62.9% |
| 2019 Q3 | 24.61 Billion KRW | 170.72% |
| 2019 Q4 | 16.07 Billion KRW | -34.69% |
| 2019 Q2 | 9.09 Billion KRW | 42.73% |
| 2018 Q1 | 9.39 Billion KRW | -46.14% |
| 2018 Q4 | 9.84 Billion KRW | 22.4% |
| 2018 Q3 | 8.04 Billion KRW | 11.86% |
| 2018 FY | 34.47 Billion KRW | -6.53% |
| 2018 Q2 | 7.19 Billion KRW | -23.42% |
| 2017 FY | 36.88 Billion KRW | 228.33% |
| 2017 Q2 | 6.54 Billion KRW | 181.65% |
| 2017 Q3 | 10.57 Billion KRW | 61.42% |
| 2017 Q4 | 17.43 Billion KRW | 64.92% |
| 2017 Q1 | 2.32 Billion KRW | 11.74% |
| 2016 Q1 | 3.55 Billion KRW | 1.61% |
| 2016 FY | 11.23 Billion KRW | -1.9% |
| 2016 Q4 | 2.08 Billion KRW | -20.21% |
| 2016 Q3 | 2.6 Billion KRW | -12.72% |
| 2016 Q2 | 2.98 Billion KRW | -15.95% |
| 2015 Q4 | 3.49 Billion KRW | 23.26% |
| 2015 Q3 | 2.83 Billion KRW | 14.82% |
| 2015 FY | 11.45 Billion KRW | -2.65% |
| 2015 Q1 | 2.64 Billion KRW | -28.04% |
| 2015 Q2 | 2.47 Billion KRW | -6.39% |
| 2014 Q1 | 2.01 Billion KRW | -48.76% |
| 2014 FY | 11.76 Billion KRW | -5.64% |
| 2014 Q4 | 3.67 Billion KRW | -11.02% |
| 2014 Q3 | 4.12 Billion KRW | 111.03% |
| 2014 Q2 | 1.95 Billion KRW | -2.91% |
| 2013 Q1 | 5.28 Billion KRW | 9.95% |
| 2013 Q3 | 968.12 Million KRW | -57.69% |
| 2013 FY | 12.46 Billion KRW | -44.14% |
| 2013 Q2 | 2.28 Billion KRW | -56.67% |
| 2013 Q4 | 3.92 Billion KRW | 305.82% |
| 2012 FY | 22.31 Billion KRW | -35.11% |
| 2012 Q2 | 5.77 Billion KRW | -11.82% |
| 2012 Q1 | 6.55 Billion KRW | -9.28% |
| 2012 Q4 | 4.8 Billion KRW | -7.32% |
| 2012 Q3 | 5.18 Billion KRW | -10.31% |
| 2011 Q2 | 10.59 Billion KRW | 18.89% |
| 2011 Q4 | 7.22 Billion KRW | -5.78% |
| 2011 FY | 34.38 Billion KRW | 16.94% |
| 2011 Q1 | 8.9 Billion KRW | 2.93% |
| 2011 Q3 | 7.66 Billion KRW | -27.62% |
| 2010 Q3 | 6.98 Billion KRW | -0.2% |
| 2010 Q2 | 6.99 Billion KRW | 3.37% |
| 2010 Q1 | 6.76 Billion KRW | 0.0% |
| 2010 FY | 29.4 Billion KRW | 758.01% |
| 2010 Q4 | 8.65 Billion KRW | 23.92% |
| 2009 FY | 3.42 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Daewoong Co., Ltd. | 1815.1 Billion KRW | 96.929% |
| PharmGen Science, Inc. | 166.77 Billion KRW | 66.572% |